Guilford restructuring
Executive Summary
Guilford plans to reduce its workforce by approximately 25% to 220 employees following suspension of several R&D programs and a decision to focus on more advanced clinical projects. The company will concentrate on the anesthetic agent Aquavan (propofol pro-drug) and the Parkinson's disease agent GPI-1485, both in Phase II studies. Guilford expects to take a restructuring charge of up to $1.5 mil. in the third quarter. The program is expected to result in estimated annualized savings of approximately $10 mil.-$12 mil., beginning in 2003...
You may also be interested in...
EU MDR Notified Body Designations Could Soar By A Third By End Of 2021
There could be 28 notified body designations in total under the Medical Device Regulation by the end of 2021. But there is cause for concern over designations under the IVD Regulation, which are lagging far behind.
Swiss Health Providers Turn Heat On Federal Council: 12% Loss Of Medtech Products Likely On EU MRA Failure
A consortium of Swiss providers, patient groups and health care trade bodies is imploring the federal council to avert a looming patient care crisis in Switzerland if the EU MRA cannot be agreed.
New China COVID Vaccine Arriving But COVAX Pledge May Need A Booster
China’s first domestically-developed recombinant protein vaccine for COVID-19 moves forward in late-stage trials in two countries.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: